Wall Street Zen Upgrades Jasper Therapeutics (NASDAQ:JSPR) to “Hold”

Jasper Therapeutics (NASDAQ:JSPR) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

A number of other equities analysts have also commented on JSPR. TD Cowen lowered shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th. Finally, Royal Bank Of Canada set a $3.00 target price on shares of Jasper Therapeutics and gave the company a “sector perform” rating in a research note on Friday, May 15th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $12.00.

Jasper Therapeutics Stock Performance

JSPR opened at $0.69 on Friday. The company has a market cap of $19.28 million, a PE ratio of -0.21 and a beta of 3.07. The stock has a 50-day moving average of $0.61 and a 200-day moving average of $1.00. Jasper Therapeutics has a 52-week low of $0.32 and a 52-week high of $3.25.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.08. On average, research analysts predict that Jasper Therapeutics will post -1.67 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in JSPR. Engineers Gate Manager LP acquired a new position in Jasper Therapeutics during the 4th quarter worth about $26,000. Panagora Asset Management Inc. acquired a new stake in Jasper Therapeutics in the 4th quarter valued at about $35,000. Acadian Asset Management LLC acquired a new stake in Jasper Therapeutics in the 1st quarter valued at about $46,000. Voleon Capital Management LP bought a new position in shares of Jasper Therapeutics in the third quarter worth about $50,000. Finally, Jain Global LLC bought a new position in shares of Jasper Therapeutics in the fourth quarter worth about $79,000. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.